BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:53 PM
 | 
Sep 22, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GSK's Trelegy Ellipta meets in Phase III IMPACT trial for COPD

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Innoviva Inc. (NASDAQ:INVA) reported data from the Phase III IMPACT trial in 10,355 chronic obstructive pulmonary disease (COPD) patients showing that once-daily Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) met the primary endpoint of reducing the annual rate of on-treatment moderate and severe exacerbations compared to both fluticasone furoate/vilanterol (0.91 vs. 1.07 exacerbations per year, p<0.001) and umeclidinium bromide/vilanterol (0.91 vs. 1.21 exacerbations per year, p<0.001). The double-blind, international trial enrolled patients with moderate to very severe symptomatic COPD and a history of...

Read the full 406 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >